Intercure Ltd(INCR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.9100
Day High1.0000
Open:0.9700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion
Tipranks
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review
Tipranks
InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate
Tipranks
InterCure Faces Nasdaq Compliance Deadline After Bid-Price Breach
Tipranks
InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans
Tipranks
InterCure Shareholders Approve All Proposals at 2025 Annual Meeting
Tipranks
InterCure Faces NIS 27 Million Exposure as Key Cannabis Partner Bazelet Enters Restructuring
Tipranks
InterCure Ltd. Schedules Annual General Meeting for December 2025
Tipranks
InterCure and Cannasoul Forge Strategic Partnership to Innovate Cannabis Therapeutics
Tipranks
InterCure Announces Strong First Half 2025 Results Amid Strategic Expansion
Tipranks
InterCure Acquires ISHI to Expand U.S. Cannabis Market Reach
GlobeNewswire
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
GlobeNewswire
InterCure Provides an Update Regarding Nir Oz Facility
GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
GlobeNewswire
InterCure Wins Cannolam Arbitration Proceeding
GlobeNewswire
InterCure Provides an Update Regarding the Security Situation in Israel
GlobeNewswire
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
GlobeNewswire
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
GlobeNewswire
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Profile

InterCure is a cannabis company. It is a licensed cannabis producer which offer good manufacturing practices certified and pharmaceutical-grade medical cannabis products. InterCure is based in NEW YORK.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.